Imatinib induced pyoderma gangrenosum

Journal of Postgraduate Medicine

Volumn 59, Issue 3, 2013, Pages 244-245

  Pinato, D J ^a,b   Sharma, R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; IMATINIB; PREDNISONE;

ABDOMINAL MASS; ADVANCED CANCER; AGED; ANAMNESIS; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEG ULCER; LETTER; MYCOSIS; PYODERMA GANGRENOSUM; SCAR FORMATION;

AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG ERUPTIONS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PREDNISONE; PYODERMA GANGRENOSUM; PYRIMIDINES; RECURRENCE; WITHHOLDING TREATMENT;

EID: 84884642190     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.118059     Document Type: Letter

References (7)

1. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-Term results from a randomized phase II trial of standard-versus higher-Dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5
2. Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): Revealing sycosis-And pyoderma gangrenosum-like lesions. Int J Dermatol 2006;45:1002-3
3. ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: Another cutaneous side-effect of sunitinib? Br J Dermatol 2008;159:242-3
4. Scheinfeld N. Imatinib mesylate and dermatology part 2: A review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006;5:228-31
5. Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial. Lancet Oncol 2010;11:942-9
6. Scott LC, White JD, Reid R, Cowie F. Management of skin toxicity related to the use of imatinib mesylate (STI571, Glivectrade mark) for advanced stage gastrointestinal stromal tumours. Sarcoma 2005;9:157-60
7. Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: A synopsis. Int J Dermatol 2004;43:39-47